EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home

Zehnjährige Erfahrung mit Home-Care bei Patient:innen mit Plasmazellerkrankungen: optimale Therapie zu Hause ermöglichen

Flavia Bigi, Mauro Fiacchini, Roberta Restuccia, Simone Masci, Gaia Mazzocchetti, Marco Talarico, Michele Puppi, Ilaria Sacchetti, Enrica Manzato, Miriam Iezza, Katia Mancuso, Chiara Sartor und 8 weitere

Clinical and Experimental Medicine · 27.05.2025 · 25 (1)

DOI: 10.1007/s10238-025-01683-2 ↗

Auf einen Blick

Bei 83 Patient:innen mit multiplem Myelom oder AL-Amyloidose war eine Heiminfusion über 2014–2023 machbar. Die Autor:innen berichten, dass die Behandlung sicher und praktikabel war.

Fragestellung

Wie machbar und sicher ist Home-Care mit Heiminfusion bei Patient:innen mit multiplem Myelom oder AL-Amyloidose?

Methode

Einzentrische retrospektive Auswertung von Heiminfusionen in Bologna zwischen 2014 und 2023.

Ergebnisse

83 Patient:innen; medianes Alter 79 Jahre, 56 % mit Performance-Status ≥ 2. Median 116 Tage Therapie, 12 Arzneigaben und 12 Hausbesuche. Zwei Drittel kamen nie in die Ambulanz.

Einschränkungen

Einzentrige retrospektive Datenerhebung.

Schlussfolgerung der Autor:innen

Die Autor:innen schlussfolgern, dass Home-Care bei diesen Patient:innen sicher und machbar war.

Kernaussagen

  • 83 Patient:innen mit MM oder AL-Amyloidose erhielten Heiminfusionen
  • Median 116 Tage Therapie, 12 Arzneigaben und 12 Hausbesuche
  • Die Autor:innen berichten sichere und praktikable Home-Care

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 27.05.2025. Verfasst von Flavia Bigi und 19 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia "Seràgnoli", Bologna, Italy. Hauptthemen laut MEDLINE: Home Care Services, Multiple Myeloma, Home Infusion Therapy, Immunoglobulin Light-chain Amyloidosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Alma Mater Studiorum - Università di Bologna.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced age at diagnosis, comorbidities and invalidating symptoms can debilitate multiple myeloma (MM) and AL amyloidosis (AL) patients, potentially precluding access to optimal therapy. The Associazione Italiana contro le Leucemie , Linfomi e Mieloma (AIL) has been providing home care to hematological patients in Italy since 1993. Between 2014 and 2023, 83 MM and AL patients received home infusion therapy through AIL in Bologna. Half were newly diagnosed, and half had undergone 1–7 prior lines of therapy. The median age was 79 years and 56% of patients had a performance status ≥ 2. The most frequently administered drugs included bortezomib (82%), daratumumab (14%), and bendamustine (9%). During the median 116-day therapy duration (range 1–750), patients received a median of 12 drug administrations and 12 home visits (range 1–59). Two-thirds of the patients never attended the outpatient clinic during home therapy. Ten newly diagnosed transplant-eligible patients were able to receive standard induction, restore their performance status, and proceed to transplantation. Twenty-one newly diagnosed transplant-ineligible patients received bortezomib and dexamethasone (with or without melphalan). At relapse, they were able to receive outpatient infusion therapy in 5 out of 11 cases. Elderly, frail patients, and patients in later relapse stages could maintain their quality of life, avoiding distressing hospital visits and remaining at home with their families while still receiving active treatment. Home therapy proved feasible in the 22 patients with AL in this study as well. Despite the limitations of a single-center retrospective data collection, our results show that home care in these patients is safe and feasible. We hope these preliminary findings may encourage the implementation of such programs by health policies in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Home Care ServicesMultiple MyelomaHome Infusion TherapyImmunoglobulin Light-chain AmyloidosisHumansAgedMaleFemaleAged, 80 and overItalyMiddle AgedRetrospective StudiesBortezomib

Stichwörter der Autor:innen

AILHome care programHome therapyMultiple myeloma

Substanzen

Bortezomib

Autor:innen und Institutionen

  • IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia "Seràgnoli", Bologna, Italy.
  • Dipartimento Di Scienze Mediche E Chirurgiche, Università Di Bologna, Bologna, Italy.
  • Associazione Italiana Contro Le Leucemie, Linfomi e Mieloma Di Bologna, Via Massarenti 9, 40138, Bologna, BO, Italy.
  • IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Istituto Di Ematologia "Seràgnoli", Bologna, Italy. e.zamagni@unibo.it.
  • Dipartimento Di Scienze Mediche E Chirurgiche, Università Di Bologna, Bologna, Italy. e.zamagni@unibo.it.

Förderung

  • Ministero della Salute
  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Bigi, F., Fiacchini, M., Restuccia, R., Masci, S., Mazzocchetti, G., Talarico, M., Puppi, M., Sacchetti, I., Manzato, E., Iezza, M., Mancuso, K., Sartor, C., Pantani, L., Tacchetti, P., Alatif, R. A., Pastore, E., Barbato, S., Cavo, M., Zamagni, E., & Rizzello, I. (2025). Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home. Clinical and Experimental Medicine, 25(1). https://doi.org/10.1007/s10238-025-01683-2

Vancouver

Bigi F, Fiacchini M, Restuccia R, Masci S, Mazzocchetti G, Talarico M, et al. Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home. Clinical and Experimental Medicine. 2025;25(1). doi:10.1007/s10238-025-01683-2

BibTeX
@article{Bigi2025,
  author = {Bigi, Flavia and Fiacchini, Mauro and Restuccia, Roberta and Masci, Simone and Mazzocchetti, Gaia and Talarico, Marco and Puppi, Michele and Sacchetti, Ilaria and Manzato, Enrica and Iezza, Miriam and Mancuso, Katia and Sartor, Chiara and Pantani, Lucia and Tacchetti, Paola and Alatif, Rania Abd and Pastore, Erica and Barbato, Simona and Cavo, Michele and Zamagni, Elena and Rizzello, Ilaria},
  title = {Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home},
  journal = {Clinical and Experimental Medicine},
  year = {2025},
  volume = {25},
  number = {1},
  doi = {10.1007/s10238-025-01683-2}
}
Kostenlos starten →